Evolus (NASDAQ:EOLS) and Stemline Therapeutics (NASDAQ:STML) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.


This table compares Evolus and Stemline Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evolus N/A N/A N/A
Stemline Therapeutics N/A -106.34% -84.63%

Analyst Recommendations

This is a summary of recent recommendations for Evolus and Stemline Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evolus 0 0 4 0 3.00
Stemline Therapeutics 0 0 4 0 3.00

Evolus presently has a consensus price target of $32.50, suggesting a potential upside of 136.02%. Stemline Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 93.80%. Given Evolus’ higher probable upside, equities analysts plainly believe Evolus is more favorable than Stemline Therapeutics.

Valuation and Earnings

This table compares Evolus and Stemline Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Evolus N/A N/A -$4.48 million ($0.27) -51.00
Stemline Therapeutics $900,000.00 532.86 -$67.82 million ($2.94) -5.27

Evolus has higher earnings, but lower revenue than Stemline Therapeutics. Evolus is trading at a lower price-to-earnings ratio than Stemline Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

13.2% of Evolus shares are held by institutional investors. Comparatively, 67.2% of Stemline Therapeutics shares are held by institutional investors. 14.8% of Stemline Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


Evolus beats Stemline Therapeutics on 5 of the 9 factors compared between the two stocks.

Evolus Company Profile

Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.